Implanet Initiates a Prospective and Multicenter Clinical Study in Partnership with TFS International

BORDEAUX, France & BOSTON–(BUSINESS WIRE)–Regulatory News:

IMPLANET (Euronext: IMPL, FR0010458729, PEA-PME eligible) (Paris:IMPL), a medical technology company specialized in vertebral and knee-surgery implants, announces the commencement of a prospective and multicenter clinical study, designed to document the outcomes of the JAZZ Band in adult degenerative and adult deformity indications.

Implanet has partnered with TFS International, a professional CRO (Contract Research Organization), to help ensure a scientifically robust study design and execution.

Ludovic Lastennet, CEO of Implanet, states: “We are pleased to announce this important first step in the establishment of our prospective multicenter US study, partnering with a highly reputable CRO to initiate and manage the project with the highest standards of quality and rigor. The JAZZ Band has tremendous potential as a tool for surgeons to augment spinal fusion in complex adult surgery. As the global leader in Band based technologies, we are excited to take a leadership position in both rapidly expanding our product portfolio and documenting clinical and economic outcomes.



Print Friendly, PDF & Email

Josh Sandberg

Josh Sandberg is the President and CEO of Ortho Spine Partners and sits on several company and industry related Boards. He also is the Creator and Editor of OrthoSpineNews.

Related Articles

Back to top button